Scott T. Aaronson, MD

Institute for Advanced Diagnosis and Therapeutics, Sheppard Pratt Hospital System, Baltimore, Maryland

JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
Zofia Kozak, Scott T. Aaronson
JCP
Pilot Study of High Frequency TMS for Bipolar Depression
Original Research

May 20, 2024

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.
Scott T. Aaronson, Eric L. Goldwaser, Paul E. Croarkin, et al
JCP
Long-Term Safety and Efficacy of Zuranolone in MDD
Original Research

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
Andrew J. Cutler, Gregory W. Mattingly, Susan G. Kornstein, et al
JCP
TMS in Anxious Depression
Original Research

January 11, 2023

Patients with anxious depression tend to have more severe depressive symptoms. This study examined the effects of transcranial magnetic stimulation in these patients.
Todd M. Hutton, Scott T. Aaronson, Linda L. Carpenter, et al
JCP
Original Research

August 21, 2018

Vagus nerve stimulation (VNS) treatment has been shown to be efficacious in treatment-resistant depression (TRD). Can VNS treatment lead to improvements in quality of life in patients with TRD...
Charles R. Conway, Arun Kumar, Willa Xiong, et al
JCP
Original Research

September 16, 2014

David L. Dunner, Scott T. Aaronson, Harold A. Sackeim, et al
JCP
Original Research

November 30, 2008

Mauricio Tohen, Eduard Vieta, Guy M. Goodwin, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe